Skip to content
March 29, 2024

Equity.Guru

Investment information for the new generation

Search

mmed.ne

Our Psychedelic Trip Isn’t Over   I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector…
MindMed (MMED.NE, MNMD.Q) announced the start of a Phase 1 trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT. DMT, properly known as N,N-Dimethyltryptamine is a psychoactive chemical…
Mind Medicine (MNMD.Q) announced the addition of Dr. Peter Bergethon to their Scientific Advisory Board. Bergethon is a “world-leading” expert in neurology, digital medicine, and central nervous system (CNS)…
Mind Medicine (MMED.NE, MNMD.Q) announced that J.R. Rahn is stepping down from his roles as CEO and director. Rahn was a co-founder of the company and was at the…
Mind Medicine (MMED.NE) announced the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase I…
It’s 2031, COVID is long gone. Jose Conseco is president of the USA. Jeff Bezos redesigns the human digestive system to not need food or water Peter Thiel spends…
MindMed (MMED.NE) announced the publication of the first study on MDMA dosing optimisation using personalised medicine. The study was conducted at the University Hospital Basel Liechti Lab, in Basel,…
“Life is too short to be small.” – Tim Ferriss, The 4-Hour Workweek Every psychedelics company starts its investor deck off with a fact about the quickly changing regulatory…